Colchicine in Patients at Cardiac Risk Undergoing Major Non-Cardiac Surgery

PHASE3RecruitingINTERVENTIONAL
Enrollment

880

Participants

Timeline

Start Date

April 20, 2025

Primary Completion Date

March 30, 2028

Study Completion Date

March 30, 2029

Conditions
Cardiovascular DiseasesCardiovascular ComplicationPerioperative ComplicationMyocardial InjuryMyocardial Injury After Noncardiac Surgery (MINS)
Interventions
DRUG

Colchicine

"Colchicine Group:~IMP = Colchicine (0.5 mg, enteral) first application in the evening before day of surgery, following a 1-0-1 regimen until the third postoperative day, ending with the application of the ninth dose. Colchicine tablets are provided as 1 mg tablets with a score, which must be divided before ingestion."

DRUG

Placebo

"Placebo Group:~Placebo (identical to IMP in appearance and application) first application in the evening before day of surgery, following a 1-0-1 regimen until the third postoperative day, ending with the application of the ninth dose. Placebo tablets are provided as tablets with a score, which must be divided before ingestion."

Trial Locations (1)

9007

RECRUITING

Cantonal Hospital St. Gallen, Sankt Gallen

All Listed Sponsors
lead

Cantonal Hospital of St. Gallen

OTHER